Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and doppler echocardiographic abnormalities, and short-term prognosis

Journal of the American College of Cardiology

Volumn 41, Issue 10, 2003, Pages 1805-1811

  D'Aloia, Antonio ^a   Faggiano, Pompilio ^b,c   Aurigemma, Gerard ^d   Bontempi, Luca ^a   Ruggeri, Giuseppina ^c   Metra, Marco ^a   Nodari, Savina ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Unità Operativa di Diabetologia piazzale Spedali Civili 1   (Italy)

^c SPEDALI CIVILI   (Italy)

^d WORCESTER STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; PROTEIN CARBOHYDRATE ANTIGEN 125; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEVICE; DOPPLER ECHOCARDIOGRAPHY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM PRESSURE; HOSPITALIZATION; HUMAN; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; UNITED STATES;

EID: 0038238871     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00311-5     Document Type: Article

References (22)

1. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414-21.
2. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine plasma renine activity and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87 Suppl VII:VII40-8.
3. Cheng V, Kazanegra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:368-91.
4. Sharma R, Rauchhaus M, Ponikowski PP, et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000;36:523-8.
5. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degree of congestive heart failure. Circulation 1995;92:1479-86.
6. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128-31.
7. Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 2002;23:70-8.
8. Bast RC, Klug TL, John ES, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
9. O'Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA125: what is known about the antigen, its structure and its function. Int J Biol Markers 1998;13:188-95.
10. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function. Am Heart J 1999;137:1044-9.
11. Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987;75:175-83.
12. Giannuzzi P, Imparato A, Temporelli PL, et al. Doppler-derived mitral deceleration time of early filling as a strong predictor of pulmonary capillary wedge pressure in postinfarction patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1994;23:1760-7.
13. AxSIM System tumor markers CA125. Package insert instructions. Abbott Park, IL: Abbott Laboratories, Diagnostics Division.
14. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-38.
15. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002;85:175-8.
16. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA125 in patients with benign and malignant ascites. Cancer 1987;59:213-7.
17. Sevinc A, Buyukberger S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA125 in hemodialysis patients with peritoneal, pleural or pericardial fluids. Gynecol Oncol 2000;77:254-7.
18. Epiney M, Bertossa C, Weil A, Campana A, Bishof P. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000;15:1261-5.
19. Seo T IkedaY, Onaka H, et al. Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 1993;57:489-94.
20. Zeimet AG, Offner FA, Marth C, et al. Modulation of CA125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 1997;17:3129-31.
21. Kubonishi I, Bandobaschi K, Murata N, Daibata M, Ido E, Sonobe H. High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Haematol 1997;98:450-2.
22. Marth C, Zeimet AG, Widschwendter M, Daxenbichler G. Regulation of CA125 expression in cultured human carcinoma cells. Int J Biol Markers 1998;13:207-9.